FDA's Risk Communications On Public Health Threats To Be Tested
Executive Summary
Agency-sponsored focus groups will assess information about medical countermeasures; project builds on previous FDA efforts to understand consumer perceptions of risk communications.
You may also be interested in...
Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals
OTC drugs with single brand for various line extensions might confuse patients, agency says. Findings could have implications for Rx risk communication as well.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Xpovio Clinical Development Timeline
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.